JP MORGAN/CALL/BOSTON SCIENTIFIC/80/0.1/20.06.25 | Real-time Bid/Ask 09:04:06 26/06/2024 BST | ||
| 1.14 EUR / 1.2 EUR | +6.36% |
|
| Current month | +4.76% | ||
| 1 month | +5.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 1.1 | -3.51% |
| 24/06/24 | 1.14 | +3.64% |
| 21/06/24 | 1.1 | +0.92% |
| 20/06/24 | 1.09 | 0.00% |
| 19/06/24 | 1.09 | +1.87% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 11:59 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | J.P. Morgan |
| WKN | JK2LLA |
| ISIN | DE000JK2LLA6 |
| Date issued | 29/02/2024 |
| Strike | 80 $ |
| Maturity | 20/06/2025 (360 Days) |
| Parity | 10 : 1 |
| Emission price | 0.35 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.2 € |
|---|---|
| Lowest since issue | 0.67 € |
| Spread | 0.06 € |
| Spread % | 5.00% |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
77.51
USD
Average target price
82.35
USD
Spread / Average Target
+6.25%
- Stock Market
- Warrants
- Warrant
